

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/087,207 02/28/2002		Patrick Jay Lutz	5408/11295-US2	7037	
7278	7590 08/08/2003				
DARBY & DARBY P.C.			EXAMINER		
P. O. BOX 525 NEW YORK,	· ·		PRYOR, ALTON NATHANIEL		
			ART UNIT	PAPER NUMBER	
			1616	111	
			DATE MAILED: 08/08/2003	2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-326 (Re		Action Summary	1	Part of Paper No. 14				
1) Notice 2) Notice 3) Inform U.S. Patent and Tr	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	· —		(PTO-413) Paper No(s) atent Application (PTO-152				
l	Acknowledgment is made of a claim for dome							
) \square The translation of the foreign language p	-		• •				
	acknowledgment is made of a claim for domes		•		lication).			
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
Copies of the certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage.								
	 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 							
ا ماره	a) ☐ All b) ☐ Some * c) ☐ None of: 1.☐ Certified copies of the priority documents have been received.							
l	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
	••	an priority under 24	SIISC & 110/a\	-(d) or (f)				
•	inder 35 U.S.C. §§ 119 and 120	-AGITIMET.						
12)	The oath or declaration is objected to by the E	• •	uon.					
11)	The proposed drawing correction filed on If approved, corrected drawings are required in a			veu by the Examiner.				
44)□-	Applicant may not request that any objection to			` '				
10)	The drawing(s) filed on is/are: a) acc	. ,	•					
1	The specification is objected to by the Examir							
	on Papers							
1	Claim(s) are subject to restriction and	or election require	ment.		,			
7)	Claim(s) 47-50 is/are objected to.							
6)	6) Claim(s) <u>1-6,11,12,14,18,22,24-27,31-46 and 51</u> is/are rejected.							
5)□	Claim(s) is/are allowed.							
	4a) Of the above claim(s) 7-10,13,15-17,19-21,23 and 28-30 is/are withdrawn from consideration.							
4)	Claim(s) 1-51 is/are pending in the applicati	on.						
Dispositi	on of Claims	parto accupio,						
3)□	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
2a)□	,—	This action is non-fi			•			
1)	Responsive to communication(s) filed on 22	-						
- If NO - Failu - Any r earne Status	period for reply is specified above, the maximum statutory perior re to reply within the set or extended period for reply will, by state eply received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	d will apply and will expire ute, cause the application t ling date of this communica	SIX (6) MONTHS from to become ABANDONED	he mailing date of this commu (35 U.S.C. § 133).	nication.			
THE I - Exter after	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR 'SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a re	l. 1.136(a). In no event, how	ever, may a reply be time	ely filed				
Period fo	or Reply	•		•	_			
	The MAILING DATE of this communication a	Alton N. Pryor	r sheet with the co	1616 rrespondence addres	S			
	Onice Action Summary	Examiner		Art Unit				
	Office Action Summary	10/087,207		LUTZ, PATRICK JAY				
,								
		Application No.		Applicant(s)	-			

Application/Control Number: 10/087,207

Art Unit: 1616

DETAILED ACTION

- I. Rejection of claim 6 under 35 USC 112, 2nd paragraph will be maintained for reasons on record. There is no antecedent basis for R4 being benzyl.
- II. Rejection of claim 45 under 35 USC 112, 2nd paragraph will not be maintained in light of amendment filed 5/27/03. The active step of claim 45 is now complete.
- III. Art Rejections (35 USC 102 and 103) on record will not be maintained in light of amendment filed 5/27/03. The Art cited in Art Rejections are to methyl benzethonium chloride which is not embraced by the instant claims.
- IV. Objection to claims 47-50 will be maintained for reasons on record.
- V. __ The elected invention is allowable for reasons on record.
- VI. Applicant must correct the definition of R4 in the specification at page 2 line 17.

Response to Amendment

Applicant's arguments with respect to claims have been considered but are moot in view of the new ground(s) of rejection. See Art rejections below.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5,11,12,24-27,33,34,44,51 are rejected under 35 U.S.C. 102(b) as being anticipated by Wan (J. of Pharmaceutical Science, 1968, vol. 57 no. 11, pp. 1903-

Application/Control Number: 10/087,207

Art Unit: 1616

6). Wan teaches a composition comprising benzethonium chloride and salicylic acid. See abstract.

Claims 1-5,11,12,24-27,33,34,44,45,51 are rejected under 35 U.S.C. 102(b) as being anticipated by Adachi et al (JP 10087496; 4/7/98). Adachi teaches a method of applying to skin (substrate) a composition comprising benzethonium chloride and salicylic acid to inhibit acne (microorganism). See abstract.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set—forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 14,18,22,31,32,35-43,46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Adachi as applied to claims 1-5,11,12,24-27,33,34,44,45,51 above in view of Biedermann et al (US 6150403; 11/21/00). See Adachi's 102(b) rejection above. Adachi teaches all that recited in claims 14,18,22,31,32,35-43,46 except for the invention comprising hydroacetic acid and glycols. However, Biedermann teaches a method of applying a composition comprising hydroacetic acid and glycols to skin to treat acne by controlling sebaceous gland activity. See abstract, column 2 lines 33-38, column 3 line 45 – column 5 line 53, column 12 line 59 – column 12 line 12. It would have been obvious to one having ordinary skill in the art to modify the invention of Adachi to include dehydroacetic acid and glycols. One having ordinary skill in the art would have been motivated to do this since compositions comprising dehydroacetic

acid and glycols treat acne by controlling sebaceous gland activity. With respect to the instant ratio of ingredients (hydroacetic acid: benzethonium chloride or salicylic acid: benzethonium chloride) the optimum ratios would have been determined through routine experimentation. One having ordinary skill in the art would have been motivated to do this in order to develop the most effective method for controlling the secretion of oils from the sebaceous gland to reduce acne.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 703 308-4691. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m. - - - - -

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703 305-3592 for regular communications and 703-305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-1235.

Alton Pryor, AU 1616

August 3, 2003